# Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells

> **NCT05208060** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Inmunotek S.L.** · enrollment: 48 (estimated)

## Conditions studied

- Immune Response

## Interventions

- **BIOLOGICAL:** MV130
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05208060
- **Lead sponsor:** Inmunotek S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-01
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05208060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05208060, "Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05208060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*